Charges hit Medtronic third-quarter profits
This article was originally published in Clinica
Acquisition and litigation charges in the third quarter of fiscal 2008 have left Medtronic with a huge dent in its coffers. Despite hiking its top-line up 12% to $3.41bn, the company's net profits sank 89% to $77m for the period.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.